Publications
Complete publication list (Pubmed search) :
>> Link
Representative publications :
Bastin-Coyette L, Smal C, Cardoen S, Saussoy P, Van den Neste E, Bontemps F.
Mechanisms of cell death induced by 2-chloroadenosine in leukemic B-cells.
Biochem Pharmacol. 2008 Apr 1;75(7):1451-60.
Smal C, Van Den Neste E, Maerevoet M, Poiré X, Théate I, Bontemps F.
Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes.
Cancer Lett. 2007 Aug 8;253(1):68-73.
Smal C, Lisart S, Maerevoet M, Ferrant A, Bontemps F, Van Den Neste E.
Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB.
Biochem Pharmacol. 2007 Feb 1;73(3):351-8.
Smal C, Vertommen D, Bertrand L, Ntamashimikiro S, Rider MH, Van Den Neste E, Bontemps F.
Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity.
J Biol Chem. 2006 Feb 24;281(8):4887-93.
Van den Neste E, Cardoen S, Offner F, Bontemps F.
Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine.
Int J Oncol. 2005 Oct;27(4):1113-24. Review.
Smal C, Cardoen S, Bertrand L, Delacauw A, Ferrant A, Van den Berghe G, Van Den Neste E, Bontemps F.
Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells.
Biochem Pharmacol. 2004 Jul 1;68(1):95-103.
Van Den Neste E, Smal C, Cardoen S, Delacauw A, Frankard J, Ferrant A, Van den Berghe G, Bontemps F.
Activation of deoxycytidine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes.
Biochem Pharmacol. 2003 Feb 15;65(4):573-80.
Van Den Neste E, Cardoen S, Husson B, Rosier JF, Delacauw A, Ferrant A, Van den Berghe G, Bontemps F.
2-Chloro-2'-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes.
Leukemia. 2002 Jan;16(1):36-43.
Cardoen S, Van Den Neste E, Smal C, Rosier JF, Delacauw A, Ferrant A, Van den Berghe G, Bontemps F.
Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.
Clin Cancer Res. 2001 Nov;7(11):3559-66.
Bontemps F, Delacauw A, Cardoen S, Van Den Neste E, Van Den Berghe G.
Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2'-deoxyadenosine.
Biochem Pharmacol. 2000 May 15;59(10):1237-43.
Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Michaux L, Sonet A, Bosly A, Doyen C, Mineur P, André M, Straetmans N, Coche E, Venet C, Duprez T, Ferrant A.
Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Leukemia. 2000 Jun;14(6):1136-42.
Van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM, Gillis E, Leveugle P, Deneys V, Ferrant A, Van den Berghe G.
Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine.
Leukemia. 1999 Jun;13(6):918-25.
